What Is IHSS in Cardiac Medicine and How It Relates to HCM

IHSS, or idiopathic hypertrophic subaortic stenosis, is a now-outdated term for the heart condition known today as hypertrophic cardiomyopathy, specifically the obstructive form where thickened heart muscle blocks blood from leaving the left ventricle efficiently. The condition affects roughly 1 in 500 people, making it the most common inherited heart disorder, and it remains the leading cardiac cause of sudden death in young athletes. Despite the name change, the underlying problem is the same one described more than sixty years ago: the muscular wall of the heart grows abnormally thick, and in many patients, that overgrowth creates a physical obstruction inside the heart’s main pumping chamber.

Why the Name Changed

The term “idiopathic hypertrophic subaortic stenosis” was coined in the early 1960s when researchers including Eugene Braunwald published landmark descriptions of the disease based on analyses of dozens of patients.¹ “Idiopathic” simply meant the cause was unknown. “Subaortic stenosis” described where the blockage sat: just below the aortic valve, in the outflow tract of the left ventricle. But several things about that label turned out to be incomplete. First, researchers eventually found that the cause is usually genetic, not truly “idiopathic.” Second, not everyone with the condition has obstruction; some people have thickened hearts that pump just fine at rest. Third, the term focused narrowly on the outflow tract when the disease affects the entire heart muscle in ways that matter beyond simple obstruction.

The field eventually settled on “hypertrophic cardiomyopathy” (HCM) as a broader, more accurate label. Within that umbrella, the obstructive form, the version that old literature called IHSS, is now typically referred to as obstructive HCM or HOCM. A detailed history of this naming debate, which spanned decades and generated real controversy among cardiologists, was published as a retrospective review tracing the fifty-year evolution from IHSS terminology to the modern HCM framework.² If you encounter the term IHSS in older medical records or family histories, it refers to the same disease that a modern cardiologist would call obstructive HCM.

How the Obstruction Actually Works

The classic explanation you’ll still find in many textbooks involves something called the Venturi effect: as blood squeezes past the thickened septum (the wall between the heart’s ventricles), it accelerates, supposedly creating a suction force that pulls the mitral valve leaflet into the outflow tract and worsens the blockage. That explanation is tidy, but research using advanced flow-mapping techniques has shown it’s not the whole story, and probably not even the main story.

Detailed imaging studies combining color Doppler data with speckle tracking have revealed that in most patients with obstructive HCM, the mitral valve actually starts moving toward the obstruction before the heart even begins squeezing. During late diastole, when the heart is still filling, incoming blood creates a swirling vortex behind the mitral valve that pushes the leaflets forward. This “diastolic anterior motion” acts as a setup for the full obstruction that develops once the heart contracts. Then, during early systole, the protruding septum redirects even low-velocity blood flow beneath the mitral valve, pushing it further forward. The dominant forces at play appear to be drag forces rather than the suction-like Venturi mechanism.³ This distinction matters clinically because it helps explain why the obstruction can be so dynamic, worsening dramatically with dehydration, standing, or exertion, and improving with maneuvers like squatting that increase blood volume in the heart.

When a doctor listens to the chest of someone with obstructive HCM, they often hear a systolic murmur that changes with body position. The murmur typically gets louder during a Valsalva maneuver (bearing down) or on standing, and can diminish or disappear entirely with a prompt squat.⁴ This dynamic quality is one of the bedside clues that distinguishes HCM obstruction from fixed types of valve narrowing.

The Genetics Behind It

HCM is inherited in an autosomal dominant pattern, meaning a single copy of a mutated gene from one parent is enough to cause the disease. The genes most commonly involved code for proteins in the sarcomere, the basic contractile unit of heart muscle cells. The two most frequently mutated genes are MYBPC3 and MYH7. A large meta-analysis covering over 7,600 patients found that MYBPC3 mutations appeared in about 20% of HCM patients and MYH7 in about 14%, while mutations in TNNT2 and TNNI3 each appeared in roughly 2%.⁵

One frustrating aspect of the genetics is that knowing which mutation someone carries doesn’t reliably predict how severe their disease will be. A study of patients screened across five sarcomeric genes found that more than half the identified mutations had not been described before, and no clear differences in the physical features of the disease were observed between carriers of different mutations.⁶ Two family members with the exact same mutation can have wildly different outcomes: one may have barely detectable thickening on an echocardiogram, while another develops severe obstruction and heart failure symptoms. This variability makes genetic testing useful for family screening but poor as a standalone tool for predicting who will do well and who will not.

Guidelines recommend that first-degree relatives of someone diagnosed with HCM undergo clinical and, when possible, genetic screening.⁷ Because there is no cure, the goal of early identification is to catch the disease before serious complications arise and to begin monitoring and, when needed, preventive treatment.⁸

What Happens at the Tissue Level

Beyond the visible thickening, the heart muscle in HCM undergoes changes at a microscopic level that drive many of the condition’s complications. The hallmark features are myocyte hypertrophy (individual muscle cells growing abnormally large), myocyte disarray (cells arranged in chaotic, swirling patterns instead of parallel lines), and interstitial fibrosis (scar-like tissue accumulating between muscle cells).⁹

Advanced MRI techniques can now detect these changes without a biopsy. One approach measures how much gadolinium contrast agent is retained by the heart muscle after injection, a marker of fibrosis. When fibrosis exceeds about 15% of the heart muscle, the risk of sudden cardiac death rises substantially.¹⁰ Newer imaging research using diffusion tensor MRI has shown that even people who carry a sarcomeric gene mutation but haven’t yet developed visible thickening already show signs of disarray in their heart muscle compared to healthy controls, and overt HCM patients show even more pronounced abnormalities.¹¹ This suggests that the disease process begins at a cellular level well before the heart looks obviously abnormal on a standard echocardiogram.

Living With Symptoms

The symptoms of obstructive HCM range from barely noticeable to profoundly life-limiting. Shortness of breath and fatigue are consistently reported as the most bothersome symptoms, and most patients say that an effective treatment would need to improve at least one of those to meaningfully change their lives.¹² Other common complaints include chest pain, dizziness, lightheadedness, and palpitations. Fainting during exertion is a red flag that warrants urgent evaluation.

The impact extends beyond physical symptoms. Patient-reported outcome research has identified emotional distress, anxiety, depression, interference with work, disrupted sleep, and strained family relationships as key ways HCM erodes quality of life.¹³ For many patients, the psychological weight of knowing they carry a potentially fatal heart condition shapes daily decisions about exercise, career, and family planning.

Drug Treatment

For decades, the first-line medications for obstructive HCM were beta-blockers and calcium channel blockers, both of which slow the heart rate, give the ventricle more time to fill, and reduce how hard the muscle contracts, all of which can ease the outflow tract obstruction. In head-to-head comparisons, the beta-blocker metoprolol was effective at reducing outflow tract pressure gradients at rest and during exercise, while verapamil (a calcium channel blocker) showed more variable effects on gradients but tended to improve patients’ self-reported ability to function at work and manage daily symptoms.¹⁴ A double-blind crossover trial found that most patients preferred active drug treatment over placebo, though peak exercise capacity was not significantly improved by either drug.¹⁵

The landscape shifted in 2022 with the approval of mavacamten, the first drug designed specifically to target the underlying mechanism of HCM. Instead of slowing the heart indirectly, mavacamten works by reducing the excessive binding between actin and myosin, the two proteins responsible for muscle contraction. By dialing down the number of active cross-bridges, it directly decreases the hypercontractility that creates the obstruction.¹⁶ In the pivotal clinical trial, mavacamten significantly improved exercise capacity, symptoms, and outflow tract pressure gradients in patients with obstructive HCM. One observational study documented that outflow tract gradients began falling within the first week of treatment, with an average resting gradient dropping from about 113 mmHg to 75 mmHg after just seven days and continuing to decline further over sixteen weeks.¹⁷ Dosing is individually titrated, with regular echocardiographic monitoring, because reducing contractility too far could weaken the heart excessively.¹⁸

When Medications Are Not Enough

If symptoms persist despite optimal drug therapy, two procedural options are well established. Surgical septal myectomy involves a cardiac surgeon physically trimming the thickened portion of the septum to widen the outflow tract. It can be performed with very low mortality at high-volume experienced centers, and long-term follow-up has shown that survival after myectomy matches that of the general population, which is significantly better than the survival of patients with obstructive HCM who do not undergo the procedure.¹⁹ ²⁰

The less invasive alternative is alcohol septal ablation, introduced in 1994. A cardiologist threads a catheter into a small artery feeding the thickened septum and injects a small amount of pure alcohol, producing a controlled, localized heart attack that thins the obstructing muscle over time. The procedure has been refined over three decades, and results are now considered comparable to those of surgical myectomy in appropriately selected patients.²¹ ²² The choice between surgery and ablation depends on anatomy, age, other medical conditions, and the expertise of the treating center. Younger patients and those with very thick septa or additional mitral valve abnormalities often fare better with surgery.

Atrial Fibrillation and Stroke Risk

Atrial fibrillation is the most common sustained rhythm disturbance in HCM, and it deserves special attention because its consequences are worse here than in the general population. Subclinical and clinical episodes occur in close to half of all HCM patients over their lifetimes.²³ The prevalence at any given time sits above 25%.²⁴

In HCM patients, atrial fibrillation carries a higher stroke risk than in people without underlying cardiomyopathy, and it can also be a marker that the disease has progressed to a more advanced stage.²⁵ For this reason, guidelines generally take a more aggressive stance on anticoagulation (blood-thinning medication) in HCM patients with atrial fibrillation compared to the general population, where the decision is typically based on a point-scoring system. In HCM, even a single episode of atrial fibrillation often tips the balance toward starting anticoagulation.

Sudden Death in Athletes and the Exercise Question

HCM is the single most common cause of sudden cardiac death in young competitive athletes, a fact that has historically led to blanket recommendations against intense sport.²⁶ But this association has also created a disproportionate fear of all exercise in anyone with the diagnosis. Surveys have found that only about 45% of HCM patients meet minimum guidelines for physical activity, and many intentionally cut back on exercise after being diagnosed.²⁷

Retrospective reviews have complicated the traditional picture. The majority of cardiac arrests in HCM patients actually occur at rest or during mild exertion, not during vigorous sport. The overall incidence of HCM-related sudden death has turned out to be lower than older estimates suggested. Growing evidence now indicates that carefully guided, moderate-intensity exercise can be both safe and beneficial for HCM patients, and the 2024 AHA/ACC management guidelines reflect this more nuanced stance, moving away from categorical bans toward individualized recommendations.²⁸ The shift is significant: a generation of patients was told to avoid physical activity entirely, which likely caused its own health harms from inactivity, obesity, and psychological stress.

Conditions That Mimic HCM

Not every thickened heart is HCM. About 10% to 15% of patients who present with a heart that looks like HCM on an echocardiogram actually have a different underlying condition, sometimes called a phenocopy.²⁹ These include cardiac amyloidosis (where misfolded proteins deposit in the heart), Fabry disease (a rare storage disorder), glycogen storage diseases, RASopathies, and mitochondrial disorders.³⁰

Distinguishing these conditions from true sarcomeric HCM matters enormously because some of them have specific treatments. Fabry disease, for instance, can be treated with enzyme replacement therapy, and certain forms of cardiac amyloidosis now have targeted drugs as well. If a patient is misdiagnosed with “garden variety” HCM, they miss out on a treatable cause. Clues to a phenocopy include an unusual pattern of thickening, involvement of other organ systems, specific ECG features, or a family history inconsistent with autosomal dominant inheritance. Cardiac MRI, genetic testing, and sometimes tissue biopsy help sort these cases out.

Pregnancy With HCM

For women with HCM considering pregnancy, the overall reassurance from the data is cautious but genuine. A systematic review covering more than 1,600 pregnancies found that maternal death occurred in about 0.2% of cases. Complications like heart failure, atrial fibrillation, and fainting occurred at single-digit rates (roughly 5%, 4%, and 9%, respectively), and the cesarean section rate was about 43%. Preterm birth occurred in about 22% of pregnancies.³¹

Longer-term follow-up data is also encouraging. A study comparing HCM patients who became pregnant against those who did not found no difference in all-cause mortality, major cardiac events, or arrhythmic events at ten years.³² Women who were asymptomatic before pregnancy generally tolerate it well; the risk is higher in those who already had symptoms or severe outflow tract obstruction before conceiving. Pre-pregnancy risk assessment and genetic counseling are recommended, beta-blockers should be continued through pregnancy, and vaginal delivery with regional anesthesia is usually appropriate.³³

How HCM Differs in Children

Pediatric HCM is a distinct entity in several ways. While the condition affects roughly 1 in 500 people overall, children who present with it are more likely to have a non-sarcomeric cause. Up to about 35% of pediatric cases stem from conditions other than the classic sarcomeric gene mutations, including RASopathies (a group of genetic syndromes affecting the Ras/MAPK signaling pathway), metabolic storage disorders, and other syndromic conditions.³⁴ This broader range of causes means that the standard adult playbook, built around sarcomeric mutations and outflow tract obstruction, often does not apply directly. Disease trajectories are more variable, treatment responses less predictable, and the stakes are higher because sudden cardiac death, while rare, is a recognized risk even in childhood. Dedicated pediatric-specific management protocols remain a significant gap in the field, and most children with HCM are managed by extrapolating from adult guidelines and case-by-case expert judgment.